Sugi Predict

Sugi Predict / Compounds / SCHEMBL87627

SCHEMBL87627

SCHEMBL87627

CCCCCOC[C@H](CO)OP(=O)(O)O

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LPAR3 Q9UBY5 10/20 0.58
▸ LPAR1 Q92633 9/20 0.58
▸ LPAR5 Q9H1C0 4/20 0.55
▸ USP2 O75604 1/20 0.51
▸ CYP2C9 P11712 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ LPAR2 Q9HBW0 6/20 0.47
▸ LPAR6 P43657 3/20 0.47
▸ LPAR4 Q99677 3/20 0.47
▸ SMPD1 P17405 3/20 0.47
▸ PLA2G2C Q5R387 1/20 0.46
▸ FGFR1 P11362 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL173661 1.00 LPAR3 (0.58) LPAR3LPAR1LPAR5USP2CYP2C9
SCHEMBL9346178 0.98 LPAR3 (0.60) LPAR3LPAR1LPAR5USP2CYP2C9
SCHEMBL7549117 0.98 LPAR3 (0.60) LPAR3LPAR1LPAR5USP2CYP2C9
SCHEMBL8724394 0.98 LPAR3 (0.60) LPAR3LPAR1LPAR5USP2CYP2C9
SCHEMBL4240007 0.90 LPAR3 (0.56) LPAR3LPAR1LPAR5LPAR2
SCHEMBL2126767 0.90 LPAR3 (0.56) LPAR3LPAR1LPAR5LPAR2
SCHEMBL10563405 0.89 LPAR3 (0.66) LPAR3LPAR1LPAR5USP2CYP2C9
SCHEMBL10566910 0.89 LPAR3 (0.66) LPAR3LPAR1LPAR5USP2CYP2C9
SCHEMBL10566055 0.88 LPAR3 (0.60) LPAR3LPAR1LPAR5USP2CYP2C9
SCHEMBL31252907 0.86 ALDH1A1 (0.58) LPAR3LPAR1LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1061947-B1 STABILIZED AQUEOUS GLUCAGON SOLUTIONS COMPRISING DETERGENTS NOVO NORDISK AS (DK) 2004-06-16 — — EP claimed
US-20030199672-A1 Derivatives of GLP-1 analogs KNUDSEN LISELOTTE BJERRE (DK) 2003-10-23 — — US claimed
US-6384016-B1 ONE PEPTIDE SELECTED FROM GLUCAGON, GLP-1, AND ANALOGUES AND DERIVATIVES THEREOF TOGETHER WITH A STABILIZING AND SOLUBILIZING AMOUNT OF AT LEAST ONE DETERGENT, SAID DETERGENT HAVING AT LEAST 2 POSITIVE CHARGES, AT LEAST 2 NEGATIVE NOVO NORDISK A/S (DK) 2002-05-07 — — US claimed
US-20010011071-A1 DERIVATIVES OF GLP-1 ANALOGS KNUDSEN LISELOTTE BJERRE (DK) 2001-08-02 — — US claimed
EP-1061947-A1 STABILIZED AQUEOUS PEPTIDE SOLUTIONS NOVO NORDISK A/S (DK) 2000-12-27 — — EP claimed
WO-1999047160-A1 STABILIZED AQUEOUS PEPTIDE SOLUTIONS NOVO NORDISK A/S (DK) 1999-09-23 — — WO claimed
WO-2023240050-A9 ANTIBODY REPURPOSING SRI INTERNATIONAL (US) 2024-05-02 — — WO disclosed
EP-4351550-A2 CRYSTALLINE FORMS OF ALDH2 MODULATORS Sophrosyne Pharmaceuticals Limited (KY) 2024-04-17 — — EP disclosed
US-11945848-B2 Chimeric inhibitor molecules of complement activation OMEROS CORPORATION (US) 2024-04-02 — — US disclosed
CN-117729915-A Crystalline forms of ALDH2 modulators 索菲洛许奈制药有限公司 2024-03-19 — — CN disclosed
US-11931350-B2 Opioid receptor ligands and methods of using and making same TREVENA, INC. (US) 2024-03-19 — — US disclosed
US-20240025949-A1 Beta-Arrestin Effectors and Compositions and Methods of Use Thereof TREVENA, INC. 2024-01-25 — — US disclosed
WO-2023240050-A2 ANTIBODY REPURPOSING SRI INTERNATIONAL (US) 2023-12-14 — — WO disclosed
EP-1123411-A1 ENZYMATIC METHODS FOR MEASURING LYSOPHOSPHOLIPIDS AND PHOSPHOLIPIDS AND CORRELATION WITH DISEASES Atairgin Technologies, Inc. (US) 2001-08-16 — — EP disclosed
US-20010011071-A1 DERIVATIVES OF GLP-1 ANALOGS KNUDSEN LISELOTTE BJERRE (DK) 2001-08-02 — — US disclosed
US-6255063-B1 DIGESTING LYSOPHOSPHATIDIC ACID IN SAMPLE WITH ENZYME TO PRODUCE GLYCEROL-3-PHOSPHATE, REACTING WITH OTHER ENZYME TO GIVE DETECTABLE BY-PRODUCT, MEASURING BY-PRODUCT TO DETERMININE CONCENTRATION OF ACID, CORRELATING WITH DISEASE ATAIRGIN TECHNOLOGIES, INC. 2001-07-03 — — US disclosed
US-6248553-B1 DETECTING DISEASE BY DIGESTING LYSOPHOSPHATIDIC ACID IN BODY FLUID SAMPLE WITH FIRST ENZYME, REACTING PRODUCED SUBSTRATE WITH SECOND ENZYME, MEASURING DETECTABLE PRODUCT, THEN COMPARING TO NORMAL CONCENTRATION; FOR GYNECOLOGICAL CANCER ATAIRGIN TECHNOLOGIES, INC. 2001-06-19 — — US disclosed
EP-1061947-A1 STABILIZED AQUEOUS PEPTIDE SOLUTIONS NOVO NORDISK A/S (DK) 2000-12-27 — — EP disclosed
WO-2000023612-A1 ENZYMATIC METHODS FOR MEASURING LYSOPHOSPHOLIPIDS AND PHOSPHOLIPIDS AND CORRELATION WITH DISEASES ATAIRGIN TECHNOLOGIES, INC. (US) 2000-04-27 — — WO disclosed
WO-1999047160-A1 STABILIZED AQUEOUS PEPTIDE SOLUTIONS NOVO NORDISK A/S (DK) 1999-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199672-A1 Derivatives of GLP-1 analogs GLP1R, GIPR, IAPP LPAR3 47/4885LPAR1 76/4885LPAR5 87/4885
US-11931350-B2 Opioid receptor ligands and methods of using and making same OPRL1, OPRK1, OPRM1 LPAR3 173/4885LPAR1 197/4885LPAR5 135/4885
US-20240025949-A1 Beta-Arrestin Effectors and Compositions and Methods of Use Thereof ARRB1, FGB, SARS1 LPAR3 107/4885LPAR1 150/4885LPAR5 280/4885
US-20010011071-A1 DERIVATIVES OF GLP-1 ANALOGS GLP1R, GIPR, IAPP LPAR3 47/4885LPAR1 76/4885LPAR5 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.